Overview

Study to Determine the Safety and Efficacy of Adalimumab in the Treatment of Pyoderma Gangrenosum

Status:
Withdrawn
Trial end date:
2007-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to see if Humira (adalimumab) is effective and safe in the treatment of pyoderma gangrenosum.
Phase:
Phase 2
Details
Lead Sponsor:
Wake Forest University
Wake Forest University Health Sciences
Treatments:
Adalimumab